- WKN: 633500
- ISIN: DE0006335003
- Land: Deutschland
Nachricht vom 25.02.2021 | 08:00
Krones AG: Krones publishes preliminary figures for 2020
DGAP-News: Krones AG
/ Key word(s): Preliminary Results
Corporate News Release
25 February 2021
Krones publishes preliminary figures for 2020
- Krones' consolidated revenue fell in 2020 as a result of the Covid-19 pandemic by 16.1% to €3.32 billion.
- Order intake was also significantly affected by corona and, at €3.31 billion, was 19.0% lower than in 2019. However, the fourth quarter showed first positive signs of improvement.
- Krones' profitability was impacted by one-time expenses of €72 million for capacity adjustments. EBITDA decreased from €227.3 million to €133.2 million. The EBITDA margin was 4.0% (previous year: 5.7%). Excluding these one-off effects, the EBITDA margin was 6.2% (previous year: 6.6%).
- Krones generated free cash flow of €221.3 million in 2020 (previous year: -€94.4 million).
- This year, based on the current situation, Krones expects business to pick up slightly and forecasts revenue growth of 2.5% to 3.5% and an improvement in the EBITDA margin to between 6.5% and 7.5% in 2021.
Krones, the leading manufacturer of filling and packaging technology, slightly exceeded its most recently outlook according to the preliminary figures for 2020.
Due to the Covid-19 pandemic, revenue fell 16.1% year-on-year, from €3,958.9 million to €3,322.7 million. This is a slightly smaller revenue shortfall than the 17% decrease forecast in early November 2020.
The uncertain general economic situation in 2020 burdened investment confidence among Krones' customers. This affected the company's order intake, primarily in the first half of the year. The contract value of orders increased significantly in the third and especially in the fourth quarter. Over the full year 2020, order intake was down 19.0% year-on-year, from €4,083.5 million to €3,307.1 million. At the end of 2020, Krones had an order backlog of €1.21 billion (previous year: €1.39 billion).
Profitability affected by corona and one-off effects
The lower order intake meant that Krones could not make optimum use of its production capacity. This impacted profitability in 2020. Savings resulting from the structural measures adopted by the company in the second half of 2019 had a positive effect on earnings. In total, earnings before interest, taxes, depreciation and amortisation (EBITDA) went down from €227.3 million in the previous year to €133.2 million in 2020. The EBITDA margin was 4.0% (previous year: 5.7%). It should be noted that EBITDA was impacted in 2020 by around €72 million in expenses for personnel-related measures. Excluding these expenses for capacity adjustment, the EBITDA margin was 6.2% in 2020 (previous year: 6.6%). This slightly exceeded the Executive Board's outlook of 5.5% to 6.0%.
Earnings before taxes (EBT) fell from €41.7 million in the previous year to -€36.6 million in 2020. In addition to the expenses for capacity adjustment, EBT was additionally reduced by goodwill impairments and value adjustments in the amount of approximately €8 million. Excluding the one-off effects totalling around €80 million, the EBT margin was 1.3%. Krones' consolidated net income came to -€79.7 million in 2020 (previous year: €9.2 million). This corresponds to earnings per share of -€2.52 (previous year: €0.30).
Free cash flow of €221.3 million significantly higher than in previous year
Free cash flow developed positively in 2020. Krones improved free cash flow by €315.7 million year-on-year to €221.3 million. In addition to reduced capital expenditure, this also reflected lower working capital. However, due to the significant revenue shortfall, the working capital to revenue ratio increased to 28.3% (previous year: 26.9%). The equity ratio was 39.4% (previous year: 41.3%). Overall, Krones continues to possess a very robust financial and capital structure.
All stated figures are preliminary and are subject to change in the course of auditing by the independent auditors. Krones publishes its Annual Report for 2020 on 25 March 2021.
Krones provides outlook for the 2021 financial year
For the 2021 financial year, due to ongoing uncertainty about the path of the Covid-19 pandemic, Krones is forecasting low revenue growth of 2.5% to 3.5%. Based on the slight recovery in revenue and the savings from the structural measures, the Executive Board expects profitability to be better than in 2020. Krones anticipates an EBITDA margin of 6.5% to 7.5% in 2021. The third key figure of the outlook, the working capital to revenue ratio, is expected to improve to between 26% and 27%.
The outlook for 2021 is subject to the assumption that there will be no severe impacts from the Covid-19 pandemic such as harmful virus mutations or vaccination difficulties. This would hit the economy and hence also Krones harder than currently expected and could lead to negative revenue and earnings effects.
|Phone:||+49 (0)9401 701169|
|Fax:||+49 (0)9401 709 1 1169|
|Listed:||Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange|
|EQS News ID:||1170965|
|End of News||DGAP News Service|
Krones AG: After strong third quarter, Krones ...
Krones AG: Preliminary announcement of the pub ...
Krones AG: Krones generates high order intake ...
Krones AG: Preliminary announcement of the pub ...
Krones AG: Krones raises full-year guidance fo ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 16:37 Allianz: Kursziel 250 Euro
03. Dezember 16:48 Update DocuSign: Minus steigt auf 40 Prozent! Der nächste ...
03. Dezember 17:00 DAX: Der nächste Nackenschlag
03. Dezember 17:54 Börsenpunk: DAX - Angst ist zurück an den Märkten - jetzt trotzdem ...
03. Dezember 18:09 Alibaba, Tencent und Co: Kleiner Crash vorm Wochenende
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021